Ascentage Pharma Group International (AAPG) SEC Filings — 2025
42 SEC filings for Ascentage Pharma Group International (AAPG) in 2025.
Filings
- Ascentage Pharma Announces Board and Committee Changes — 6-K · Dec 31, 2025
- Ascentage Pharma to Present at J.P. Morgan Healthcare Conference — 6-K · Dec 17, 2025
- Ascentage Pharma Group International 6-K Filing — 6-K · Dec 9, 2025
- Ascentage Pharma Presents Lisaftoclax Data at ASH Meeting — 6-K · Dec 8, 2025
- Ascentage Pharma Group International 6-K Filing — 6-K · Dec 5, 2025
- Ascentage Pharma Group International 6-K Filing — 6-K · Dec 1, 2025
- Ascentage Pharma Grants RSUs and Share Options — 6-K · Nov 28, 2025
- Ascentage Pharma GIST Drug Data Published in Nature — 6-K · Nov 25, 2025
- Ascentage Pharma to Attend 3 Investor Conferences in December — 6-K · Nov 19, 2025
- Ascentage Pharma to Present Olverembatinib Data at ASH 2025 — 6-K · Nov 4, 2025
- Ascentage Pharma to Present at Investor Conferences — 6-K · Oct 30, 2025
- Ascentage Pharma to Attend 3 Investor Conferences in October — 6-K · Oct 7, 2025
- Ascentage Pharma to Attend 3 Investor Conferences in September — 6-K · Aug 28, 2025
- Ascentage Pharma Reports 2025 Interim Financials — 6-K · Aug 21, 2025
- Ascentage Pharma's Lisaftoclax Trial Cleared by FDA & EMA — 6-K · Aug 18, 2025
- Ascentage Pharma Announces Board Meeting — 6-K · Aug 8, 2025
- Ascentage Pharma to Announce H1 2025 Results Aug 20 — 6-K · Aug 7, 2025
- Ascentage Pharma to Present at Evercore China Biotech Summit — 6-K · Aug 1, 2025
- Ascentage Pharma Closes Share Placing and Subscription — 6-K · Jul 25, 2025
- Ascentage Pharma Closes Share Placement — 6-K · Jul 17, 2025
- Ascentage Pharma Enters Placing and Subscription Agreement — 6-K · Jul 15, 2025
- Ascentage Pharma's Lisaftoclax Approved in China for CLL/SLL — 6-K · Jul 10, 2025
- Ascentage Pharma Names New CFO and SVP — 6-K · Jul 8, 2025
- Ascentage Pharma Grants More RSUs — 6-K · Jun 27, 2025
- Ascentage Pharma Presents Olverembatinib Data at EHA 2025 — 6-K · Jun 16, 2025
- Ascentage Pharma Assets to be Presented at EHA Congress — 6-K · Jun 10, 2025
- Ascentage Pharma Presents Promising Alrizomadlin Data at ASCO 2025 — 6-K · Jun 3, 2025
- Ascentage Pharma's Lisaftoclax Shows Promise at ASCO 2025 — 6-K · May 23, 2025
- Ascentage Pharma Reports AGM Poll Results — 6-K · May 20, 2025
- Ascentage Pharma Presents Preclinical Cancer Study Results — 6-K · Apr 28, 2025
- Ascentage Pharma drugs in CSCO 2025 Guidelines — 6-K · Apr 21, 2025
- Ascentage Pharma Files 2024 Annual Report — 6-K · Apr 17, 2025
- Ascentage Pharma Group International 20-F Filing — 20-F · Apr 16, 2025
- Ascentage Pharma: Trustee Buys Shares for RSU Scheme — 6-K · Apr 8, 2025
- Ascentage Pharma Trustee Buys Shares for RSU Scheme — 6-K · Mar 31, 2025
- Ascentage Pharma Files 6-K for March 2025 — 6-K · Mar 27, 2025
- Ascentage Pharma to Present Pipeline Data at AACR 2025 — 6-K · Mar 26, 2025
- Ascentage Pharma Files 6-K for March 2025 — 6-K · Mar 12, 2025
- Ascentage Pharma Files Routine 6-K Report — 6-K · Mar 6, 2025
- Ascentage Pharma Changes Company Secretary — 6-K · Feb 25, 2025
- Ascentage Pharma Partially Exercises ADS Over-Allotment Option — 6-K · Feb 14, 2025
- Ascentage Pharma Partially Exercises ADS Over-Allotment Option — 6-K · Feb 11, 2025